Novavax, a clinical-stage vaccine company, has appointed Brian Rosen as Vice President, Government Affairs and Policy. He will be responsible for leading government affairs and policy efforts that are instrumental to patient access to Novavax vaccines. His efforts will be focused on the company's lead product candidates, including its RSV vaccine franchise, and quadrivalent seasonal and pandemic influenza vaccine candidates.
Rosen comes to Novavax with more than 20 years of industry and patient advocacy experience, the vast majority in government affairs, advocacy, reimbursement and policy work. He was most recently Chief Policy, Advocacy and Patient Access Officer for the Leukemia & Lymphoma Society, where he oversaw all legislative and regulatory efforts and the delivery of patient services nationwide.
Before that he developed and ran the Government Affairs, Policy and Alliance Development functions for MedImmune, which developed Synagis, a monoclonal antibody used to prevent RSV disease in premature newborns, and FluMist, a live attenuated influenza vaccine.
